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The variations in recovery time, complications, and survival among cardiac patients who have undergone coronary
artery bypass graft (CABG) procedures are vast. Many formulas and theories are used to predict clinical outcome
and recovery time, and current prognostic predictions are based on medical and family history, lifestyle, co-
morbidities, and performance status. The identification of biomarkers that provide concrete evidence supporting
clinical outcome has greatly affected the field of medicine, helping clinicians in many medicine sub-specialties to
forecast clinical course. Recent studies have discovered biomarkers that may be used as predictors of cardiac
patients’ status post-cardiothoracic surgery, and the applications are numerous. In this review, we assess currently
available cardiac biomarkers as predictors of clinical outcome for post-operative CABG patients. Data were collected
from various studies in which cardiac biomarkers were measured in pre-operative and post-operative CABG
patients.
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Introduction
Humans exist in an environment full of stress-inducing
factors, such as microorganisms, poor dietary choices,
family history, or emotional hardship, which can all im-
pact human health. Our successful survival has depended
on effective mechanisms that prevent or assist in adapting
to such taxing events. These defense mechanisms include
the immune system, which is comprised of multiple mo-
lecular pathways that respond to traumatic stress. How-
ever, the timing and intensity of the immune reaction
varies between individuals, especially during cardiothor-
acic surgeries. Thus, not every patient will have a smooth
recovery post-op, or a ten-day hospital course when bat-
tling hospital-acquired pneumonia. This diversity of re-
sponse will be highlighted in this discussion.
Each organ system of the human body has developed
specific mechanisms for injury response. For example,
stress to the skin may cause induration and erythema to* Correspondence: ksuh@hackensackUMC.org
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distribution, and reproduction in any mediuman inflamed area, whereas the intestines often manifest
inflammation by a change in bowel habits. This review
will focus on the mechanisms of the heart and how the
cardiac system responds to stress. Specifically, current
data regarding biomarkers of inflammation will be exam-
ined to determine whether these markers can be used to
predict clinical outcomes and overall patient survival.
The cardiovascular system is intricately extensive, and
takes the brunt of many stress-inducing factors. According
the American Heart Association and American Stroke As-
sociation in 2006, cardiovascular disease was the leading
cause of mortality in the United States. While not every
individual will endure a myocardial infarction, develop
cardiomyopathy, or suffer from coronary artery disease,
each person reacts to cardiovascular strain differently, and
it is this aspect that provides the unique pathophysiology
of the cardiovascular system.
One of the most common pathologies of the heart,
coronary artery disease (CAD), is precipitated by the
gradual deposition of fat and cholesterol to form athero-
sclerotic plaques in coronary vessels. The formation of
these plaques reduces the diameter of the lumen of the
vessels, thereby impairing antegrade myocardial blood
flow. A stenotic coronary artery results in reducedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and nutrients delivered to the myocardium. When the
heart is starved of oxygen and nutrients, it may become
ischemic. This ischemia can be completely asymptomatic
or manifest as angina. Prolonged ischemia may result in
death of cardiac tissue, which is a permanent condition.
Depending on the severity of the coronary artery dam-
age, patients may develop a partial blockage that may only
result in transient ischemia and angina, or a complete
blockage resulting in a myocardial infarction (MI). MI is
defined as myocardial cell death due to prolonged ische-
mia [1]. MI is detected when blood levels of sensitive and
specific biomarkers such as cTn (cardiac troponins I and
T) or the MB fraction of creatine kinase (CKMB) are in-
creased [1]. The trend of these biomarkers can indicate
how acute the infarct is, the severity and if a re-infarct has
occurred after the initial incident. This information is
extremely helpful in clinical management of a patient with
an infarct.
Coronary artery bypass grafting
Numerous procedures are currently used to treat coron-
ary blockages, including the use of tissue plasminogen
activator (TPA), cardiac catheterization and coronary
artery bypass grafting (CABG). During a CABG, a
healthy artery or vein, typically the saphenous vein from
the medial side of either lower extremity or the internal
mammary artery from the chest wall, is grafted to bypass
the blocked coronary artery. The three most commonly
affected vessels are the left anterior descending artery
(LAD), commonly known as the widow maker, the left
circumflex artery, and the right coronary artery (RCA).
A CABG procedure usually takes 3 to 5 hours, and
can include a single or multiple vessel bypass (Table 1).
During the surgery, thoracic exploration is performed
through a median sternotomy. Medication is administered
to arrest the heart, an approach known as cardioplegia,
which allows the surgeon to work on a stopped heart. The
aorta is cross-clamped, and blood flow is then re-routed
through the cardiopulmonary bypass machine during the
procedure. After the case is completed and sinus rhythm
of the heart is restored, the heart-lung bypass machine is
removed.
An alternative procedure, off-pump CABG is performed
on a beating heart. It is indicated for high-risk patients
who are not stable enough to use the cardiopulmonary
bypass machine for prolonged periods of time. These pa-
tients often have a history of peripheral vascular disease,
cerebral vascular accidents (CVA), or multiple transient is-
chemic attacks (TIAs).
The CABG procedure is complex and does not come
without risk. Cardiac surgery is a highly invasive pro-
cedure that can potentially lead to further myocardial
insult. The degree of insult is dependent on multiplefactors such as the type and extent of the surgical pro-
cedure, duration of cardiopulmonary bypass and aortic
cross-clamping, pre-operative condition of the heart,
length of anesthesia use and timing of post-operative re-
vascularization [33].
Cardiac surgery with the cardiac bypass machine
causes an acute inflammatory response through activa-
tion of inflammatory cells, complement cascade, and se-
cretion of cytokines and chemokines. Vascular endothelial
cells are activated and increase leukocyte adhesion mole-
cules, a marker for inflammation. This same response also
occurs once the cross-clamp is released and the heart is
re-perfused [34]. It is understood that during the use of
CPB, and after reperfusion, a rise in the production of free
radicals occurs that causes damage to the vasculature, also
known as reperfusion injury [35].
Serum biomarkers
Protein biomarkers
A major biomarker in the heart is serum cardio-specific
troponin T. Troponin T is one of three proteins of the
troponin regulatory complex found on tropomyosin, a
protein involved in the contractile apparatus of cardiac
muscle. Troponin T is integral to muscle contraction in
skeletal and cardiac muscle. Although typically present
at low levels in the heart, its levels rise after cardiac
surgery, before returning to baseline levels. Troponin T
levels have been shown to correlate with the duration of
cardioplegia [33]. Recently, a new highly sensitive and spe-
cific immunoassay to detect cardiac troponin T in the
serum was introduced. A promising and potential applica-
tion for this marker is better prediction of patient out-
come and a clearer understanding of the extent of cardiac
damage [36]. As stated above, inducing cardioplegia
does not come without risk, and some patients are able
to tolerate longer hours in cardioplegia than others
before suffering repercussions. This assay will help iden-
tify the patients more susceptible to damage secondary
to cardioplegia.
In addition to Troponin T and IL-6, cardiac troponin I
(CTn1), myoglobin, creatine kinase (CK) and its isoen-
zyme creatine kinase-myocardial band (CK-MB), which
is specific to the heart, are all involved in cardiac in-
flammation. Serum concentrations of these protein bio-
chemical markers are increased during acute coronary
syndrome (ACS), pericarditis, cardiac surgery and renal
dysfunction [37-39]. CTn1, CK, CK-MB and myoglobin
are released from damaged cardiac cells into the inter-
stitial space. Serum concentrations of these biomarkers
are elevated during cardiac surgery, renal dysfunction,
and pericarditis [37]. Levels of cTn1 increased after use
of the CPB machine [40].
In addition to C-reactive protein, tetranectin is a plasma
protein found in secretory cells such as monocytes. Upon
Table 1 Different heart conditions and general characteristics (listed in decreasing order of occurrence)
Condition Length of operation Mean age Gender differences Mortality rate Treatment Prevalence
Coronary Artery
Bypass Graft (CABG)
4-6 hours [2,3] Usually >60 [3] Majority occurs in
males [4]
1.53 deaths per 1000
admissions [5]
Vein or artery used to
create detour around
blocked area in artery
About 427,000 operations




30 minutes – 3
hours [7]
Congenital [2] About 2:1 ratio, men
to women [2]
1 in 1000 procedures
[8]
Balloon placed inside
aorta, then expanded [3]
Nearly one million performed
per year in the US [9] (.003%)
Aortic Regurgitation 2-5 hours [2] Prevalence increases
with age, but severe
AR is uncommon
before 70 [10]
13% of men versus
8.5% of women [10]












Aortic Stenosis 2-5 hours [2] Can develop around
30 but mostly in
patients 65 or older
[14]
3 times more






Less than 200,000 people in
US population [14]: .064%
Symptomatic: 25%
1 year from onset of
symptoms and 50% at
2 years[14]
Atrial Septal Defect 2-3 hours [12] Congenital [15] 3 times more
common in women
than in men [16]
Surgical repair in the
first 2 decades of life
is associated with a
mortality rate near
zero. [13]
Surgical closure of shunt 1.6 per 1000 live births [16] .




About .05% of births in the
US.
Tetralogy of Fallot 2-3 hours [19] Congenital [20] Unrelated [20] <10% with surgery;
without surgery,
death usually occurs
by age 20. [11]
Widen pulmonary tract
and repair VSD
5 out of every 10,000 babies






67% males[22] Lethal without
surgery. Stage 1
survival: 68-77%. [23]
Parts of left side of heart
do not develop fully
.16-.36 per 1000 live births
[22]
(3 surgeries in total) .026% of all live births
Heart Transplant Anywhere from 4–
12 hours, depending
on the person [24]
48+/−11.8 years [25] 72.4% male [26-28] Survival rate at
12 months: 88% for
men, 77.2% for
women [24]
Heart is replaced by
donor heart
















37, 102 procedures from
1986 to 2004 [31]















Table 1 Different heart conditions and general characteristics (listed in decreasing order of occurrence) (Continued)
Anastomosis Less than 30 minutes
[31]
Congenital [2] Mortality rate highest
in neonates <1 week.
Mortality rate during,
or within one month,




Free ends of aorta are
reconnected
83 patients between 1999
and 2000 [31]
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monocyte migration to the site of injury. High concentra-
tions of tetranectin are found in areas of regenerating
muscle and are associated with tissue remodeling [41].
B-type natriuretic peptide (BNP), a protein commonly
used to evaluate heart failure, is a polypeptide secreted
by the ventricles of the heart in response to excessive
stretching of cardiac myocytes. This molecule is respon-
sible for decreasing systemic vascular resistance and
central venous pressure as well as an increasing natri-
uresis. This adaptive response allows for the reduction
of systemic blood pressure, decrease in afterload, and
therefore increase in cardiac output. Measuring BNP is
an indirect way to evaluate ventricular function and iden-
tify patients at risk that may be asymptomatic. Using this
marker to stratify patients prior to CABG can help elimin-
ate the need for additional testing. Although checking a
patient’s BNP level is typically reserved for patients admit-
ted for congestive heart failure exacerbation, with the
current data indicating BNP as a marker for pre-op and
post-op patient outcome, ordering a BNP for pre-op clear-
ance may become more mainstream. Especially in patients
with a history of CAD, increased BNP levels are associated
with an increased rate of myocardial infarction and car-
diovascular death during mid-term follow-up. BNP levels
are a prognostic marker associated with higher mortality
in patients with myocardial infarction, cardiogenic shock,
and pulmonary embolism.
NT-proBNP, another established marker for cardiac
failure, is also present in other pathologies, such as ex-
acerbated chronic obstructive pulmonary disease, acute
coronary syndromes, atrial fibrillation, and myocarditis.
In contrast to BNP, higher NT-proBNP levels are associ-
ated with female gender, impaired renal function, and
older age. NT-pro-BNP is one of the biomarkers in-
creased by myocardial ischemia or subsequent, bur-
dened wall stress.Adhesion molecule biomarkers
Several adhesion molecules have also been identified to
play essential roles as cardiac inflammation biomarkers.
E-selectin, also known as CD62 antigen-like family
member E (CD62E), is an endothelial-leukocyte adhesion
molecule. It plays an important part in recruiting leuko-
cytes to a site of injury. The local release of cytokines by
damaged cells induces the overexpression of E-selectin
on endothelial cells of nearby blood vessels. As the in-
flammatory response progresses, chemokines released by
injured tissue enter the blood and activate rolling leuko-
cytes, which then tightly bind to the endothelial surface
and exit the blood vessels via diapedesis. Leukocytes
migrate through the interstitium to the site of injury or
infection guided by chemotactic signals. The levels of E-selectin were found to be the highest in the right atrium
and the lowest in the left ventricle [42].Cytokine biomarkers
Certain cytokines have been discovered to be closely re-
lated to the inflammatory cascade and also can be used
as biomarkers to trend response to cardiac stress. While
patients are on the CPB machine, pro-inflammatory cy-
tokines such as tumor necrosis factor alpha (TNF-α) and
interleukins (IL) 1, 6 and 8 are released and mediate the
systemic inflammatory response syndrome (SIRS), which
is believed to play an essential role in myocardial ische-
mia and reperfusion injury [43]. Table 2 describes some
of these and other markers. Comparing the extent of ele-
vation of these markers among patients will help ascer-
tain those that are more at risk for reperfusion injury.
IL-6 is a polypeptide secreted by activated monocytes
and endothelial cells that initiates the acute phase of the
inflammatory cascade and decreases cardiac contractil-
ity. This decline in cardiac output secondary to decrease
in contractility is a response seen in patients who are in
shock. This also leads to a drop in blood pressure. It is
this decrease in perfusion that leads to damage of the
myocardium. The level of IL-6 steadily increases during
CABG, reaching its peak in the 6th hour of the proced-
ure. This indicates that patients with a higher amount of
IL-6 at hour 6 might suffer from greater drops in cardiac
contractility, thus a decrease in cardiac output and lower
blood pressure and therefore insufficient circulation to
the myocardium.Coagulation cascade biomarkers
While the coagulation cascade may not appear to be dir-
ectly related to inflammation, the risk of coagulopathic
events increases when inflammation is present, and this
attribute can be used as a marker for stress. Anti-
thrombin 3 is a substance in blood plasma that inactivates
thrombin during the clotting cascade, and is elemental in
preventing post-operative deep vein thrombosis (DVT)
and pulmonary embolism (PE). Its levels fell significantly
post-op [40], indicating that risk for developing DVT or
PE status post-CABG is increased. This is strong evidence
promoting the importance of anticoagulation status post-
CABG and early ambulation.
The Von Willebrand factor (vWF) protein is involved
in the intrinsic pathway of the coagulation cascade. It is
bound to factor VIII and activated by thrombin. This
helps to induce the binding of platelets and eventually
clot formation. Increased plasma levels of vWF in a large
number of cardiovascular, neoplastic and connective tis-
sue diseases are presumed to arise from adverse changes
to the endothelium, and may contribute to an increased
risk of thrombosis.
Table 2 Various inflammatory biomarkers (Gene) and brief descriptions
Gene biomarker Description Increased/Decreased/Remained constant after surgery
S-TnT Part of the troponin complex Increased to 1.26 μg/L1 day after surgery; decreased to .52 μg/L
4 days after surgery [33]
NSE Enzyme; levels increase after brain damage Rises to 20.2 ng/mL postoperatively but returns to normal levels
48 h postop [44]
HSP 70 Helps with protein folding and transport Increased to about 2000 pg/mL during surgery but decreased to 0
by 19 hrs postop [45]
TLRs Signaling receptors for HSPs Decreased during operation but increased postop [45]
TNF-α Quantity correlated to the quantity of HSP70 Increased in both MUF and non-MUF groups during surgery;
normalized 24 h postop [40]
IL-1ra Inflammatory cytokine Clear rise in both MUF and non-MUF groups. Reached peak 6 hrs
postop in both groups but returned to baseline levels 12 hrs
postop in MUF group, while staying at a higher level in the non-
MUF group [40]
IL-8 Neutrophil chemotactic and activating factor Levels did not change much in group with SIRS but increased to
about 46 pg/mL in the group with MODS and continued to
decrease after [46]
IL-18 Induce chemokines. Involved in inflammatory
response following extracorporeal circulation
Remained constant in group with SIRS but increased to 300 pg/
mL 1 day postop and remained about that level in group with
MODS [46]
IL-1β Biologically inactive precursor molecule In the MUF group, IL-1β rose to max levels post-op. Fell
significantly post-op and remained at these levels. IL-1β levels
remained constant [40]
IL-6 Quantity correlated to the quantity of HSP70 Levels rose after surgery to about 100 pg/mL and remained
through days 1 and 2 after surgery [47]
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Breath biomarkers
While a variety of hematological markers are used to
monitor pre-op and post-op status, less invasive techniques
have also been utilized. An excellent study performed by
Pabst et al. determined that oxidative and metabolic stress
during cardiac surgery could be monitored by breath bio-
markers. They assessed acetone, isoprene, and pentane,
and found that acetone release was an indicator of stress
and isoprene levels correlated with cardiac output. Acetone
in the breath mirrors other metabolic stresses, such as
diabetic ketoacidosis [23]. The increased acetone is second-
ary to stress-induced release of catecholamines, which
cause increased lipolysis and release of cortisol. This corti-
sol surge results in increased dextrose turnover. Concen-
trations of ketone bodies are increased when dextrose
metabolism is impaired and lipolysis is triggered, and even-
tually acetone is generated. There is a positive relationship
between exhaled acetone levels and post-operative tropo-
nin T, as well as pre-op CRP and exhaled acetone levels.
The correlation between breath acetone level and clinical
condition underlies the potential of using breath biomarker
monitoring for diagnostic methods and timely initiation of
life-saving therapy [23].
Pabst et al. also assessed reactive oxygen species (ROS)
and the release of ethane and pentane during peroxida-
tion of omega 3 and omega 6 fatty acids. During CABG,exhaled pentane levels decreased immediately after the
sternotomy was performed. Exhaled pentane concentra-
tions measured immediately after termination of extra-
corporeal circulation correlated with the CK:CKMB
ratio measured a few hours later, suggesting that ex-
haled pentane might serve as a fast and direct bio-
marker for early recognition of oxidative stress and
ischemic reperfusion injury. Together this suggests that
pentane acts as a fast and direct biomarker [23].
Biomarkers in outcomes studies
Numerous studies have investigated pre-operative and
post-operative variables that influence the outcome of
CABG patients. Evaluating factors such as co-morbidities,
family history, and diet can help anticipate problems that
may ensue during the procedure or obstacles that might
impede recovery time. While these aspects are very influ-
ential with regard to determining patient outcome, asking
patients about family history and diet does not always
guarantee an accurate answer. The use of biomarkers to
predict prognosis serves as a more concrete method and
eliminates variables that could alter the data.
Fernandez et al. demonstrated that patients with re-
cent or ongoing ischemia exhibited higher preoperative
cardiac troponin I, CK, CKMB, and myoglobin concen-
trations in pericardial fluid than in serum [37]. Possible
mechanisms involved in this pericardial accumulation of
specific and non-specific myocardial markers include
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tion of the cardiomyocyte membrane and augmented
vascular and epicardial permeability. As a consequence
of myocardial ischemia, the integrity of the cell mem-
brane is compromised, and cytosolic proteins may be re-
leased into the myocardial interstitium, accounting for
protein leakage from the heart into the pericardial cavity.
In addition, heightened capillary and pericardial perme-
ability may increase the macromolecular exchange of tis-
sue and plasma proteins [37].
Eikvar et al. compared post-CABG levels of cardiac
markers in groups of patients that suffered from post-
operative MI and those that did not [33]. The first post-
operative day patients with postoperative myocardial
infarction (POMI) had higher levels of serum troponin T
and CK-MB compared to those that did not suffer from
a POMI. At day 4, the difference in serum troponin T
was more pronounced. The finding made by Katus et al.
that the duration of cardioplegia correlates with the
levels of serum troponin T has provided much needed
information regarding the use of troponin T as an essen-
tial tool for evaluating the degree of myocardial damage
[48]. Measuring these levels peri-operatively may aid in
anticipating the risk of POMI and perhaps in its preven-
tion. If elevated levels of serum troponin T and CK-MB
prior to CABG are found, risk stratification can aid in pre-
op planning and optimizing for surgery. Enforcing the im-
portance of weight loss, exercise, medication compliance
and exercise may result in a more positive post-op course.
BNP is secreted primarily by the muscle cells of the
pumping chambers in the heart as a response to increased
stress. Elevated levels of postoperative BNP during the
first several days after CABG surgery is known to be asso-
ciated with increased mortality. However, further research
has analyzed whether BNP is also associated with poorer
long-term physical function.
A study performed by Morimoto et al. found that
plasma levels of BNP are markedly elevated in the acute
phase after cardiac surgery requiring bypass and reflect
the left ventricular function at the same time. Further-
more, myocardial damage due to ischemia may participate
in the mechanism of synthesis and secretion of BNP [49].
The study examined the concentration of BNP immedi-
ately after CABG and followed the course during cardiac
rehabilitation (CR). After CABG, the level of BNP was ele-
vated, with the highest value immediately post-op, and
showed a downwards trend following the procedure.
A study performed on CABG surgery patients at
Brigham and Women’s Hospital in Boston and the Texas
Heart Institute in Houston both pre- and post-operatively
focused on levels of BNP and post-op outcome. Increased
levels of postoperative BNP were found to be significantly
associated with poor physical function six months to two
years status post-CABG.Wazni et al. found that patients with atrial fibrillation
following cardiac surgery exhibited higher BNP levels
than patients who remained in sinus rhythm throughout
the post-operative course [50]. When considering that
CABG patients with higher BNP levels are at an in-
creased risk for both mortality and poor post-op out-
come, it is imperative that these patients are considered
for early and aggressive medical surveillance and treat-
ment programs aimed at reducing BNP levels [51].
Both BNP and its counterpart, the N terminal fragment
of proBNP, are established markers for cardiac failure.
Schachner et al. determined the influence of preoperative
serum NT-proBNP on postoperative outcome and mid-
term survival in patients undergoing coronary artery
bypass grafting (CABG) [52]. In general, patients with ele-
vated pre-op NT-ProBNP exhibited a higher rate of com-
plications. Patients with NT-proBNP levels greater than
502 ng/l had more co-morbidities than those with NT-
proBNP levels less than 502 ng/l. Postoperatively, those pa-
tients had a significantly longer time before they were able
to be weaned from the vent, a longer ICU stay, a higher
rate of renal failure requiring hemofiltration, a higher rate
of IABPs, and a higher rate of postoperative atrial fibrilla-
tion. Atrial fibrillation is a common complication after car-
diac surgery. Although it is easily manageable with rate
controlling agents and anticoagulation, if uncontrolled it
can affect cardiac output and put patients at risk for CVA.
Preoperative measurement of NT-proBNP levels can
be used to determine CABG patients with an increased
risk as shown above. Patients with increased NT-proBNP
should have close follow-up and periodic monitoring.
Mayer et al. found that CABG patients with NT-proBNP
levels > 862 pmol exhibited decreased long-term survival
rates without clinical manifestation of heart failure. There-
fore, elevated preoperative serum NT-proBNP levels are
associated with a higher postoperative early and mid to
long-term mortality, as well as morbidity, in patients
undergoing isolated CABG [52].
vWF is a protein found in the endothelium that plays
an essential role in platelet adhesion, and functions as a
biomarker for endothelial dysfunction and damage. vWF
was shown to be a predictor of ischemic heart disease in
healthy individuals and patients with angina or acute MI
[53]. Certain intra-operative variables, such as the extent
of the surgical procedure, duration of use of the bypass
machine, and amount of ischemia from cross clamping,
are reported to be higher in patients who developed
post-operative MI [33]. In patients with elevated vWF,
special consideration can be taken in length of cross-
clamping and duration on CPB machine. This finding of
elevated vWF was also associated with blood type O. As
all patients are typed and screened prior to CABG to
prepare blood for transfusion, patients with blood type
O could also be screened for vWF for risk assessment
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level are at risk for post-op MI and ischemic stroke [54],
certain precautions should be taken in light of the in-
creased chance of poor outcome.
CPB has generally been associated with increased
levels of plasma soluble adhesion molecules of the endo-
thelium, which have been attributed to the activation
and injury of endothelial cells. Thus, the availability of
useful biochemical markers for evaluating the endothe-
lial state post-operatively offers a useful, non-invasive
means to assess return of the endothelium to the unper-
turbed state, which is important in improving patient
outcome [53]. Among the relevant markers, E and P
selectins were found to be the most influential. These
adhesion molecules mediate the initial steps of weak and
reversible leukocyte diapedesis. They play a role in the
migration of activated leukocytes into the interstitium
where they degranulate and promote inflammation. Ele-
vated levels of E and P selectin have been found in
patients suffering from hyperlipidemia, PAD (peripheral
artery disease), and CAD. High levels of these selectins
reflect platelet activation and induce procoagulation activ-
ity associated with vascular thrombotic disease. Plasma
selectins have been shown to predict major cardiovascular
events in patients with pre-existing PAD or CAD [53].
While it is useful to study a certain patient population
before, during, or after a CABG procedure, it can also be
very helpful to focus on the same population through-
out the entire process. Panagiotopoulous et al. measured
concentrations of E and P selectins, tetranectin, von
Willebrand Factor, and angiotensin converting enzyme
in patients undergoing CABG prior to and up to 3 days
after their procedure [53]. These markers were compared
with patient demographics and multiple perioperative
characteristics [53]. Differences in levels among markers
between patients correlated with the degree of pre-
existing endothelial damage and atherosclerosis.
Panagiotopoulos et al. assessed persistence of elevated
biomarker levels in the post-operative CABG period. The
post-operative period begins in the first moments when
the patient’s chest is closed, and the patient is extubated
and taken to the cardiac surgical intensive care unit. This
is a critical period, during which the patient’s vitals and
overall clinical performance must be closely monitored to
avoid complications. Panagiotopoulos et al. concluded that
of all molecules exhibiting elevated levels, tetranectin
(TN) remained elevated on the 3rd day post-operatively in
the majority of patients, while other markers decreased
[53]. This could be explained by the fact that tetranectin is
found in areas of tissue remodeling and muscle repair.
Preventing inflammation
The purpose of using biomarkers to predict post-operative
outcomes of cardiac patients is to improve survival andquality of life. Other methods have been developed that
help prevent adverse outcomes, such as the use of hep-
arin. Heparin is a highly sulfated glycosaminoglycan pro-
duced by endothelial cells that functions as an innate
anticoagulant. It can be injected as an anticoagulant, ad-
ministered intravenously, and used to form an inner anti-
coagulant surface on various experimental and medical
devices, such as test tubes and dialysis machines.
A study performed by Ljunghusen et al. assessed the
level of inflammation between two groups of CABG
patients, one for which the bypass machine was heparin-
ized and one for which it was not [55]. C3a, as well as
MAC-1 (macrophage-1 antigen), was increased in the
group that was treated using the non-heparinized ma-
chine. The results demonstrated that heparin coating in-
creased biocompatibility, resulting in less activation of
complement and a reduction in circulating monocytes
and granulocytes during the procedure [55]. There was a
reduction in the number of granulocytes after five mi-
nutes of bypass, and a highly significant reduction in
granulocytosis evident the morning after the procedure,
suggesting that an increase in expression of L-selectin
was found in the group with heparinized bypass but not
in the group without heparin.
As mentioned above, the use of heparinized systems
not only aids in a reduction of granulocytosis but also
affects the expression of HLA-DR. The percentage of
monocytes expressing HLA-DR inversely correlated with
the risk of developing postoperative infections following
major resectional surgery as well as survival after severe
trauma. There was no difference in the expression of
HLA-DR during or after bypass surgery, but HLA-DR ex-
pression was lower the morning after surgery in patients
with heparinized than in non-heparinized CPB systems
(Table 3). L-selectin levels were elevated in both groups
during bypass. Granulocyte cell counts decreased during
bypass, but normalized after the procedure. C3a desArg is
a degradation product of C3a, both of which reflect
complement activation during inflammatory response and
disease. C3a mediates inflammatory reactions such as
smooth muscle contraction, histamine release from mast
cells, vasodilatation, and chemotaxis of eosinophils.
The use of modified ultrafiltration (MUF) has proven to
be helpful in achieving electrolyte balance in fluid over-
loaded patients as well as in ridding inflammatory media-
tors associated with the use of the cardiopulmonary. MUF
has been shown to decrease transfusion requirements and
improve post-operative oxygenation and myocardial con-
tractility in children after CPB [40]. However, whether the
reduction in inflammatory response is due to decreases
in the pro-inflammatory cytokines, increases in anti-
inflammatory cytokines, or both remains unknown.
In addition to MUF, sodium nitroprusside (SNP) has
also been found to help in regaining homeostatis after
Table 3 Various inflammatory biomarkers (Serum) and brief descriptions
Serum biomarker Description Increased/Decreased/Remained constant after surgery
S-CKMB Rise in amount in blood indicates that muscle
damage has occurred
Increased to 40 μg/L1 day after surgery; decreased to 3 μg/L 4 days
after surgery [33]
CD11b/CD18 Adhesion protein No significant difference between SNP/non-SNP patients[32];
Expression of CD11b increased in group with heparin coating [37]
HLA-DR Major histocompatibility complex Significantly lower morning after operation [37]
CD62L L-selectin Increased during surgery but normalized the morning after [37]
Monocytes Activation triggers production of cytokines Decreased to 448 × 106 cells/L during surgery; increased to 1889 ×
106 cells/L the next morning [37]
C3a desArg Mediates inflammatory reactions Increased in noncoated group during surgery; levels decreased the
morning after surgery [37]
Granulocytes A type of white blood cells categorized by the
presence of granules
Reduction of circulating granulocytes noted in both groups after
surgery; increased the morning after [37]
ATIII Inactivates thrombin Levels fell significantly in groups with and without MUF filtration.
Reached baseline values 12 h postop.[40]
F1 + 2 Prothrombin fragment Rose significantly in both MUF and non-MUF groups. Fell to baseline
values 6 h postop. [40]
CXC /CC-chemokine
receptors
Act mainly on neutrophils and lymphocytes Postoperative expression of CXCR2 but not CXCR1 was significantly
lower in patients with cyanotic vs. noncyanotic heart lesions [56,57]
GCP-1 Granulocyte chemotactic protein Levels remained unchanged during study period [56]
ENA-78 Epithelial neutrophil-activating peptide Decreased from 908 pg/mL to 729 pg/mL during surgery and
remained at low levels 3 h after surgery (376 pg/mL) [56]
MPO Marker of primary neutrophil granules Increased from 11.3 ng/mL before surgery to 45.4 ng/mL during
surgery and remained at that level 3 hrs after surgery [56]
PCT Hormone produced by the thyroid Increased to 17 ng/mL 1 day postop and decreased throughout the
next 3 days [46]
Pre-albumin Anti-acute phase protein synthesized in liver Significantly lower during operation in cold priming group; levels
were almost normalized 24 hrs after surgery [35]
HSCRP Highly sensitive C-reactive protein Levels rose 30 fold by 24 hrs post-op in cold priming group and 18
fold by 24 hrs post-op in the warm priming group [35]
α-1 antitrypsin Protease inhibitor: inhibits enzymes that bind
peptides together
Decreased by half during surgery then increased 24 hrs postop in
cold priming group; decreased by half during surgery in the warm
priming group also, but increased 3 fold 24 hrs postop [35]
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reperfusion injury in experimental studies. It has mul-
tiple physiological effects, such as blocking free radicals,
inhibiting platelet aggregation, regulating membrane
permeability, and decreasing the effects of leukocytes.
During the reperfusion period of a CABG, the produc-
tion of nitric oxide (NO) is decreased, and this induces
the expression of adhesion molecules, such as the mem-
brane attack complex. Elevated levels of the membrane
attack complex result in increased neutrophil adhesion
to the endothelium. SNP was found to be effective at
controlling hypertension during CPB, and its use de-
creases the need for vasodilators in the early post-
operative period [34]. SNP has a cardio-protective effect
attributed to its induction of nitric oxide synthase
resulting in production of NO. NO reduces reperfusion
injury in experimental studies, and has been shown to
block super oxide radicals, inhibit platelet aggregationand adhesion, regulate the permeability of the endothe-
lial layer, and inhibit the function of leukocytes.
A study was performed with two groups of patients
undergoing CPB: the control group received a 5% dex-
trose solution after the release of the aortic cross-clamp,
and the SNP group was given 0.5 μg/kg/min SNP [34].
No significant difference was found between groups in
the expression of CD11b/CD18 (Table 3). Significant
increases of IL-6 were detected three hours after the ter-
mination of CPB, with a significant difference between
groups at that point. There were significant increases in
both groups in neutrophil counts, and a gradual de-
crease of platelet counts in both groups during the pro-
cedure. During CPB, vasodilator infusion for the control
of hypertension was not needed for any of the patients
in the SNP group, but was needed for 50% of patients in
the control group. During their ICU stay, patients re-
ceived vasodilators for 39.2 ± 20.6 hours in the control
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the SNP group stayed significantly shorter in the ICU:
28.2 ± 9.3 vs. 53.0 ± 15.9 hours. No blood analysis abnor-
malities were detected in any of the groups in the early
post-operative period, but one patient in the control group
expired secondary to ventricular arrhythmia resulting in
decreased cardiac output on post-operative day 3 [34].
Adenosine was found to have a cardio-protective effect
during open heart surgery. Adenosine could be used in
ischemic preconditioning (IPC) as an adjunct to cross-
clamping the aorta. Compared with simple cold blood
cardioplegia in heart valve replacement patients, adeno-
sine pretreatment (100 μg/kg/min, 10 min) as an adjunct
to 1 mM adenosine cold blood cardioplegia may reduce
CTnI, IL-6, and IL-8 release, resulting in reduced myocar-
dial injury after surgery [43]. The leakage of these cyto-
kines causes post-op myocardial dysfunction and damage.
Adenosine A1 receptors and possibly A3 receptors are
also known to confer protection through inhibitory G
protein coupled pathways and receptor activation on
cardioprotective agents such as mitochondria [43].
Buyukates et al. found that the use of warm priming
solution in open heart surgery resulted in significant im-
provements in acute inflammatory markers [35]. Levels
of highly sensitive C-reactive protein (HSCRP) increased
10–2,000 fold within 6–12 hours, and α-1 antitrypsin
increased 2–5 fold within 24 hours (Table 3). The use of
warm priming solution also had favorable outcomes in
hemodynamic parameters of the patients during and
after the surgery, such as lowest mean arterial blood
pressure (MABP) during cross clamping and highest
MABP after cross clamping, and more frequent spontan-
eous beating of the heart following removal of the cross
clamp. The 36°C warm priming solution prevented
sudden and rapid changes in the systemic circulation,
resulting in marked improvement in the systemic in-
flammatory response and more stable hemodynamic
status [35].
When considering the markers discussed above, at-
tempts made to lower these values peri-operatively by ex-
ercise, change in diet, medication or other mechanisms
may prove to be beneficial in improving patients’ post-op
course. We discovered that using heparinized machines,
modified ultrafiltration and warm priming solution in
anticipation of possible adverse events has aided in more
positive post-op courses. If modifying pre-op factors
would help reduce unfavorable outcomes, then further
evaluating the markers of inflammation may prove to be
beneficial. In conjunction with these methods to prevent
inflammation or adverse effects, measurements of BNP,
troponin and CRP levels, for example, several months
prior to CABG would provide helpful information and the
possibility of decreasing these markers and altering post-
CABG outcomes.Conclusions
Previous studies have reported biomarkers that were ele-
vated or depressed during the CABG procedure or post-
operatively. However, the majority of these studies did
not investigate correlations between levels of markers
and patient outcome. While we know that a rise in cer-
tain markers indicates that the cardiac system has been
stressed, it is not clear if high levels indicate and correl-
ate with more stress, and therefore a worse recovery
course. Our objective was to examine the literature on
cardiac biomarkers and identify associations regarding
outcome from the current published data. Expression of
the monocyte marker, HLA DR, was found to be in-
versely proportionate to the risk for developing post-
operative infections. HLA DR may prove to be useful if
examined pre-operatively, and could possibly be used as
an indicator of risk of post-operative infection. An im-
portant correlation was made between exhaled pentane
concentrations measured after coming off the CPB ma-
chine. This non-invasive biomarker may aid with early
recognition of oxidative stress and ischemic reperfusion
injury. Early awareness and treatment of tissue damage
can help prevent further injury. High levels of P and E
selectins may also predict major cardiovascular events in
patients with pre-existing PAD or CAD [23]. This can be
helpful when considering pre-operative work up labs,
specifically for patients with a past medical history of
heart disease. Von Willebrand Factor may be useful as a
biomarker for endothelial dysfunction and damage. The
prospect of developing the means to predict ischemic
heart disease in healthy individuals and patients with an-
gina or acute MI is exciting, and could potentially alter
medical care in the future [23]. The use of biomarkers is
fairly well established in other fields of medicine, such as
oncology, however is not well explored in predicting car-
diac patient prognosis. Our hope is that biomarkers will
become routinely used in this field and will help to im-
prove patient outcome.
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